Drug Profile
JAK-3 SCID gene therapy
Alternative Names: SCID gene therapy; SCID JAK-3 gene therapyLatest Information Update: 02 Feb 2017
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Gene therapies
- Mechanism of Action Gene transference; Lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 02 Feb 2017 Discontinued - Phase-I for Immunological disorders in USA (Parenteral)
- 27 Aug 2003 A preclinical study has been added to the Immunological disorders pharmacodynamics section
- 24 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Immunological disorders therapeutic trials section